

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7969416

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BAUDAX BIO, INC.	03/29/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ALKERMES PHARMA IRELAND LIMITED
<b>Street Address:</b>	CONNAUGHT HOUSE
<b>Internal Address:</b>	1 BURLINGTON ROAD
<b>City:</b>	DUBLIN 4
<b>State/Country:</b>	IRELAND
<b>PROPERTY NUMBERS Total: 10</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7459283
Patent Number:	8323641
Patent Number:	8512727
Patent Number:	10471067
Patent Number:	10709713
Patent Number:	10463673
Patent Number:	10881663
Patent Number:	11458145
Application Number:	17820783
Application Number:	17287489
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)672-5399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2026725300
<b>Email:</b>	ipdocketing@foley.com, swalker@foley.com
<b>Correspondent Name:</b>	FOLEY & LARDNER LLP
<b>Address Line 1:</b>	3000 K STREET, NW
<b>Address Line 2:</b>	SUITE 600
<b>Address Line 4:</b>	WASHINGTON, D.C. 20007
<b>ATTORNEY DOCKET NUMBER:</b>	029318-2966

<b>NAME OF SUBMITTER:</b>	MICHELE M. SIMKIN
<b>SIGNATURE:</b>	/Michele M. Simkin/
<b>DATE SIGNED:</b>	05/23/2023
<b>Total Attachments: 12</b> source=Baudax_Patent_Assignment_Agreement#page1.tif source=Baudax_Patent_Assignment_Agreement#page2.tif source=Baudax_Patent_Assignment_Agreement#page3.tif source=Baudax_Patent_Assignment_Agreement#page4.tif source=Baudax_Patent_Assignment_Agreement#page5.tif source=Baudax_Patent_Assignment_Agreement#page6.tif source=Baudax_Patent_Assignment_Agreement#page7.tif source=Baudax_Patent_Assignment_Agreement#page8.tif source=Baudax_Patent_Assignment_Agreement#page9.tif source=Baudax_Patent_Assignment_Agreement#page10.tif source=Baudax_Patent_Assignment_Agreement#page11.tif source=Baudax_Patent_Assignment_Agreement#page12.tif	

## PATENT ASSIGNMENT

This Patent Assignment (“**Patent Assignment**”), dated as of March 29, 2023 (“**Effective Date**”), is by and between Alkermes Pharma Ireland Limited, a limited liability company organized under the laws of Ireland, whose registered address is Connaught House, 1 Burlington Road, Dublin 4, Ireland (“**Purchaser**”), and Baudax Bio, Inc., a Pennsylvania corporation, with an address of 490 Lapp Road, Malvern PA 19355 (“**Seller**”). Seller and Buyer are sometimes referred to herein individually as a “**Party**” and collectively as the “**Parties**.”

WHEREAS, Purchaser and Buyer have entered into that certain Asset Transfer Agreement, dated as of March 29, 2023 (“**Asset Transfer Agreement**”); and

WHEREAS, Seller is the owner of the Patents owned or Controlled by a Seller Group Member and solely related to the Product, including the Patents set forth on Schedule A (collectively, “**Acquired Patents**”);

WHEREAS, in connection with the Asset Transfer Agreement, Purchaser has agreed to purchase from Seller and Seller has agreed to sell, convey, assign, transfer and deliver to Purchaser all of Seller’s rights, title and interest in and to the Acquired Patents.

NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements contained in the Asset Transfer Agreement, as well as other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:

1. **Defined Terms.** Unless otherwise specifically provided herein, capitalized terms used in this Patent Assignment and not otherwise defined shall have the meanings ascribed to them in the Asset Transfer Agreement.

2. **Conveyance and Acceptance of Acquired Patents.** In accordance with the provisions of the Asset Transfer Agreement, (a) Seller hereby sells, conveys, assigns, transfers and delivers to Purchaser (and to Purchaser’s successors and permitted assigns), all of its right, title and interest in and to the Acquired Patents, including all common law rights therein, and the right to claim priority to the Acquired Patents, together with all proceeds, benefits, privileges, causes of action, and remedies relating to the Acquired Patents, all rights to bring an action, whether at law or in equity, for infringement or other violation of the Acquired Patents against any third party, all rights to recover damages, and profits and injunctive relief for infringement or other violation of the Acquired Patents, provided, that no such rights are being assigned hereunder with respect to any Excluded Assets or Excluded Liabilities, and (b) Purchaser hereby accepts such sale, conveyance, assignment, transfer and delivery.

3. **Recordation.** Seller hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the respective patent office or other Governmental Authority in any jurisdiction other than the United States, to record this Assignment. All costs and expenses, including third party filing and recordation fees and other disbursements, associated with the conveyance of the Acquired Patents and with the recordation of this Patent Assignment shall be borne solely by Purchaser.

4. **Asset Transfer Agreement Controls.** Notwithstanding anything to the contrary in this Patent Assignment, nothing contained herein shall supersede, amend, modify, waiver or affect the provisions, including the representations, warranties, covenants, agreements or any of the rights and obligation of Purchaser or Seller, set forth in the Asset Transfer Agreement. This Patent

Assignment is subject to, and governed entirely in accordance with, the terms of the Asset Transfer Agreement.

5. **Further Assurances.** Seller agrees, at Purchaser's expense, to take such further action and to execute and deliver, or cause to be executed and delivered, such further instruments and take such other actions as may be necessary or desirable to carry out the transactions contemplated by this Patent Assignment, including signing all papers and documents, taking all lawful oaths and doing all acts necessary or required to be done to vest, perfect or confirm of record or otherwise in Purchaser any and all right, title and interest in, to and under any of the Acquired Patents.

6. **Counterparts.** This Patent Assignment may be executed in multiple counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement. This Patent Assignment may be executed by facsimile or electronic (.pdf) signature and a facsimile or electronic (.pdf) signature shall constitute an original for all purposes.

*[Signature Page Follows]*

IN WITNESS WHEREOF, the Parties have executed this Patent Assignment as of the Effective Date.

**PURCHASER:**

**ALKERMES PHARMA IRELAND LIMITED**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Its: \_\_\_\_\_

**SELLER:**

**BAUDAX BIO, INC.**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Its: \_\_\_\_\_

*[Signature Page to Patent Assignment]*

IN WITNESS WHEREOF, the Parties have executed this Patent Assignment as of the Effective Date.

**PURCHASER:**

**ALKERMES PHARMA IRELAND LIMITED**


By: \_\_\_\_\_

Name: \_\_\_\_\_

Its: \_\_\_\_\_

**SELLER:**

**BAUDAX BIO, INC.**

By:  \_\_\_\_\_  
B057A1A13FED4E5...

Name: Gerri Henwood

Its: Chief Executive Officer

*[Signature Page to Patent Assignment]*

**Schedule A**  
**Patents**

ANNEX 1.1(a) -- Acquired Intellectual Property

Case Number	Country	Case Type	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date	Title	Owner Name	Status
	United States of America	ORD	10/357514	04-Feb-2003	2003-0185869	02-Oct-2003	7459283	02-Dec-2008	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	Baudax Bio, Inc.	Granted
148428.00901	United States of America	CON	12/292091	12-Nov-2008	2009-0074875	19-Mar-2009	8323641	04-Dec-2012	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	Baudax Bio, Inc.	Granted
148428.00911	United States of America	ORD	10/784900	24-Feb-2004	2004-0229038	18-Nov-2004	8512727	20-Aug-2013	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
148428.01001	European Patent Convention	PCT	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01003	European Patent Convention	DIV	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01023	European Patent Convention	DIV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01033	Japan	PCT	2006-532300	27-Feb-2004	2007-505154	08-Mar-2007	4891774	22-Dec-2011	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
148428.01004	Japan	DIV	2010-233858	27-Feb-2004	2011-042670	03-Mar-2011	5548092	23-May-2014	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned



148428.01031	United States of America	CON	15/437534	21-Feb-2017	2017-0157061	08-Jun-2017	10471067	12-Nov-2019	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
148428.01071	United States of America	CON	16/560239	25-Aug-2019	2019-0381062	19-Dec-2019	10709713	14-Jul-2020	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
148428.01041	United States of America	CON	15/950367	11-Apr-2018	2018-0228809	16-Aug-2018	10463673	05-Nov-2019	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
148428.01005	Canada	PCT	2517679	27-Feb-2004	2517679	13-Jan-2005	2517679	10-Apr-2012	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01015	Belgium	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01016	France	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01017	Germany	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	602004021107.9	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01018	Hungary	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01019	Ireland	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01025	Italy	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	502009901749875	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01026	Spain	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01027	Switzerland	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01028	United Kingdom	EPP	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
148428.01029	Austria	EDV	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01034	Belgium	EDV	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01035	Switzerland	EDV	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING	Baudax Bio, Inc.	Granted - To be abandoned



	Hong Kong	REP	17102503.7	27-Feb-2004	1228765	10-Nov-2017	1228765	11-Oct-2019	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01053	Austria	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01055	Switzerland	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01057	Germany	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01058	Denmark	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01059	Finland	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01065	United Kingdom	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01067	Ireland	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01069	Netherlands	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01075	Sweden	EDV	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
148428.01076	United States of America	ORD	16/297020	08-Mar-2019	20190275053	12-Sep-2019	10881663	05-Jan-2021	METHOD OF TREATING PAIN IN ELDERLY PATIENTS WITH MILD RENAL IMPAIRMENT	Baudax Bio, Inc.	Granted
148428.01101	United States of America	ORD	16/297095	08-Mar-2019	20190275054	12-Sep-2019	11458145	04-Oct-2022	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Granted
148428.01201											

PATENT

REEL: 063736 FRAME: 0289

Annex 1.1(a)-4

ACTIVE/122415645.5

148428.01203	European Patent Convention	PCT	19764737.3	08-Mar-2019	3761977	13-Jan-2021			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
	Japan	PCT	2020-571332	08-Mar-2019	2021-527697	14-Oct-2021			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
148428.01204	China (People's Republic)	PCT	201980004945.1	08-Mar-2019	111201020	26-May-2020			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
148428.01208	United States of America	ORD	17/820783	08-Mar-2019					METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
148428.01211	Hong Kong	RCN	62020020480.3	08-Mar-2019	40032144	19-Mar-2021			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
148428.01218	Korea, Republic of	PCT	10-2020-7027716	08-Mar-2019	10-2020-0130334	18-Nov-2020			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending
148428.01209	New Zealand	PCT	767981	08-Mar-2019					METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
148428.01206	Australia	PCT	2019231858	08-Mar-2019					METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
148428.01207	Hong Kong	RCN	62020021461.2	23-Oct-2019	40031604	12-Mar-2021			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending - To be abandoned
148428.01318											

148428.01308	China (People's Republic)	PCT	201980004887.2	23-Oct-2019	111356453	30-Jun-2020	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending - To be abandoned
148428.01304	Japan	PCT	2021-521960	23-Oct-2019	2022-505572	14-Jan-2022	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
148428.01304	Korea, Republic of	PCT	10-2021-7013779	23-Oct-2019	10-2021-0081354	01-Jul-2021	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
148428.01309	Australia	PCT	2019364416	23-Oct-2019			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
148428.01307	New Zealand	PCT	775856	23-Oct-2019			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
148428.01306	Canada	PCT	3117209	23-Oct-2019	3117209	30-Apr-2020	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
148428.01305	European Patent Convention	PCT	19876037.3	23-Oct-2019	3870163	01-Sep-2021	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending - To be abandoned
148428.01303									

148428.01315	Russian Federation	PCT	2021114360	23-Oct-2019					METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
148428.01301	United States of America	PCT	17/287489	21-Apr-2021	2021-0386753	16-Dec-2021			METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
148428.01307	Australia	PCT	2019374827	07-Nov-2019					METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned
148428.01507	Canada	PCT	3118952	07-Nov-2019	3118952	14-May-2020			METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending
148428.01505	European Patent Convention	PCT	19881104 4	07-Nov-2019	3876910	15-Sep-2021			METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned
148428.01503	Japan	PCT	2021-524241	07-Nov-2019	2022-506696	17-Jan-2022			METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending
148428.01504	Korea, Republic of	PCT	10-2021-7015337	07-Nov-2019	10-2021-0089175	15-Jul-2021			METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned
148428.01509	New Zealand	PCT	776380	07-Nov-2019					METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending
148428.01506									METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	

PATENT

REEL: 063736 FRAME: 0292

Annex 1.1(a)-7

ACTIVE/122415645.5

RECORDED: 05/23/2023